The Medicines Company has acquired Rempex Pharmaceuticals for $474 million
The Medicines Company paid Rempex equity holders $140 million in an upfront payment at the closing of the deal.
The Medicines Company has agreed to pay Rempex equity holders milestone payments subsequent to the closing, including certain development and regulatory approval milestones totaling $214 million, and commercial milestones totaling $120 million.
The Medicines Company has acquired several anti-infective assets as a result of the transaction: Carbavance, Minocin IV, RPX-602, and a preclinical developmental program of novel investigational agents.
The Medicines Company will market Minocin IV (Minocycline for Injection) in the United States for resistant infections due to Acinetobacter.
View the full article at CNBC
For further deal information visit Current Agreements (subscription required)
Report: Merger and Acquisition Terms and Agreements
Report: Partnering Deals and Alliances with Novartis
Report: Partnering Deals and Alliances with Roche
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity